Prothena (PRTA) Price & Analysis

Compare

652 Followers

PRTA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.00 - $0.00

Previous CloseN/A

Volume58.73K

Average Volume (3M)972.29K

Market Cap

$0.00

Enterprise Value$0.00

Total Cash (Recent Filing)$371.44M

Total Debt (Recent Filing)$9.78M

Price to Earnings (P/E)―

Beta0.00

Next Earnings

Oct 30, 2025

EPS Estimate

-0.78

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.34

Shares Outstanding0

10 Day Avg. Volume871,238

30 Day Avg. Volume972,291

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)1.53

Price to Sales (P/S)5.51

P/FCF Ratio-4.95

Enterprise Value/Market CapN/A

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$22.06

Price Target Upside213.80% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Innovative Dosing RegimenThe company’s decision to evaluate 200 mg and 400 mg doses using a once-monthly regimen underscores confidence in PRX012’s potential and reflects a patient-friendly dosing model, particularly well-suited for subcutaneous administration in Alzheimer’s patients.

Strategic Partnership PotentialMAD data showing robust plaque reduction while maintaining lower ARIA rate can be encouraging for strategic partnership.

Therapeutic Potential Of PRX012Favorable amyloid plaque reduction was observed alongside ARIA rates comparable to placebo, suggesting that PRX012 can exert therapeutic effects at lower concentrations without exacerbating risk.

Bears Say

Discontinuation Of BirtamimabPRTA is discontinuing development of birtamimab after it failed to significantly delay mortality significantly in the phase 3 AFFIRM-AL study.

Financial ImplicationsThe discontinuation of birtamimab has led to a reduction in the price target from $30 to $14.

Operational AdjustmentsThe company said it will now work on reducing operating expenses that will include and won’t be limited to a substantial workforce reduction.

Prothena News

Prothena announces Novo Nordisk to advance coramitug into Phase 3

Prothena (PRTA) announced that Novo Nordisk (NVO) communicated during their second quarter 2025 earnings call on August 6...

1d ago

NVO

PRTA

Prothena reports Q2 EPS ($2.34), consensus ($1.79)

Reports Q2 revenue $4.4M, consensus $5.4M. Net cash used in operating and investing activities was $46.4 million in...

3d ago

PRTA

Prothena’s Coramitug Advances to Phase 3 with Novo Nordisk

An announcement from Prothena ( ($PRTA) ) is now available. On August 6, 2025, Prothena announced that its...

1d ago

PRTA

Prothena’s Strategic Initiatives and Promising Alzheimer’s Pipeline Drive Buy Rating

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Prothena, with a...

2d ago

PRTA

Prothena Reports Q2 2025 Financial Results and Pipeline Progress

Prothena Corporation ( ($PRTA) ) has released its Q2 earnings. Here is a breakdown of the information Prothena...

3d ago

PRTA

PRTA Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Prothena Corporation (PRTA) is scheduled to report 2nd quarter earnings on 08/04/2025, after the market closes. Regarding Q2...

5d ago

PRTA

Prothena Secures Leadership with New Executive Agreements

The latest update is out from Prothena ( ($PRTA) ). On July 30, 2025, Prothena Biosciences Inc entered...

8d ago

PRTA

Closing Bell Movers: GMS up 15% on takeover proposal from QXO

Ahead of Juneteenth market holiday on Thursday, U.S. equity future are little changed in the opening hour of...

2M ago

APG

GMS

Prothena Announces Major Workforce Reduction to Cut Costs

Prothena ( ($PRTA) ) has provided an update. On June 18, 2025, Prothena Corporation plc announced a significant...

2M ago

PRTA

Prothena up 3% after announcing corporate restructuring, cash burn update

16:37 EDT Prothena (PRTA) up 3% after announcing corporate restructuring, cash burn update Published first on TheFly –...

2M ago

PRTA

Prothena sees 2025 net cash burn from operating/investing at $170M-$178M

Based on the reorganization, Prothena (PRTA) is “revising its full year 2025 financial guidance and expects its 2025...

2M ago

PRTA

Prothena Chief Regulatory Officer Karp, Chief People Officer Ford to depart

On June 18, 2025, Prothena (PRTA) “announced that in connection with the workforce reduction, the employment of Carol...

2M ago

PRTA

Prothena announces corporate restructuring, cuts 63% of workforce

Prothena (PRTA) “announced that the company has initiated an approximate 63% reduction in its workforce to substantially reduce...

2M ago

BMY

NVO

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus

Stock market futures are up slightly. Enthusiasm has been tempered by geopolitical risks and uncertainty ahead of Wednesday’s...

2M ago

AMZN

PRTA FAQ

What was Prothena Corporation’s price range in the past 12 months?

Prothena Corporation lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.

What is Prothena Corporation’s market cap?

Prothena Corporation’s market cap is $0.00.

When is Prothena Corporation’s upcoming earnings report date?

Prothena Corporation’s upcoming earnings report date is Oct 30, 2025 which is in 84 days.

How were Prothena Corporation’s earnings last quarter?

Prothena Corporation released its earnings results on Aug 04, 2025. The company reported -$2.34 earnings per share for the quarter, missing the consensus estimate of -$1.254 by -$1.086.

Is Prothena Corporation overvalued?

According to Wall Street analysts Prothena Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Prothena Corporation pay dividends?

Prothena Corporation does not currently pay dividends.

What is Prothena Corporation’s EPS estimate?

Prothena Corporation’s EPS estimate is -0.78.

How many shares outstanding does Prothena Corporation have?

Prothena Corporation has 0 shares outstanding.

What happened to Prothena Corporation’s price movement after its last earnings report?

Prothena Corporation reported an EPS of -$2.34 in its last earnings report, missing expectations of -$1.254. Following the earnings report the stock price went up 1.297%.

Which hedge fund is a major shareholder of Prothena Corporation?

Currently, no hedge funds are holding shares in PRTA

Prothena Stock Smart Score

Underperform

Fundamentals

Return on Equity

-66.85%

Trailing 12-Months

Asset Growth

-38.18%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Prothena Corporation

Prothena Corporation plc is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving protein misfolding and cell adhesion, primarily in the fields of neurology and immunology. The company leverages its scientific expertise in protein dysregulation and its proprietary antibody-based technologies to develop potential treatments for diseases such as Alzheimer's disease, Parkinson's disease, and amyloidosis.

Prothena (PRTA) Earnings & Revenues

Historic Earnings Reports

PRTA Stock 12 Month Forecast

Average Price Target

$22.06

▲(213.80% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","82":"$82","22.75":"$22.8","42.5":"$42.5","62.25":"$62.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":81,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$81.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,22.75,42.5,62.25,82],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.81,12.516923076923076,18.223846153846154,23.93076923076923,29.637692307692305,35.34461538461538,41.05153846153846,46.75846153846154,52.465384615384615,58.17230769230769,63.879230769230766,69.58615384615383,75.29307692307692,{"y":81,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.81,7.983076923076923,9.156153846153845,10.329230769230769,11.502307692307692,12.675384615384615,13.848461538461539,15.021538461538462,16.194615384615386,17.36769230769231,18.540769230769232,19.713846153846156,20.886923076923075,{"y":22.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.81,6.593846153846154,6.377692307692308,6.161538461538461,5.945384615384615,5.729230769230769,5.513076923076923,5.296923076923077,5.0807692307692305,4.864615384615385,4.648461538461539,4.432307692307692,4.216153846153846,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.31,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.27,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.23,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.81,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.81,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >